上皮性卵巣がんの未治療患者におけるアベルマブ（JAVELIN OVARIAN 100）

基本情報

NCT ID

NCT02718417

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

998

治験依頼者名

Pfizer

概要

This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.

対象疾患

介入

依頼者（Sponsor）

実施施設 (16)